Brain lipid binding protein (FABP7) as modulator of astrocyte function

Physiological Research

Volumn 60, Issue SUPPL.1, 2011, Pages

  Kipp, M ^a,b   Clarner, T ^b   Gingele, S ^b   Pott, F ^b   Amor, S ^b,c   Van Der Valk, P ^b   Beyer, C ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Astroglia; Multiple sclerosis; Oligodendrocyte; Regeneration; Remyelination

Indexed keywords

CARRIER PROTEIN; CUPRIZONE; FABP7 PROTEIN, HUMAN; FABP7 PROTEIN, MOUSE; FATTY ACID BINDING PROTEIN; NERVE PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL; ASTROCYTE; CHEMICALLY INDUCED DISORDER; DEMYELINATING DISEASE; DISEASE MODEL; HUMAN; METABOLISM; MULTIPLE SCLEROSIS; MYELIN SHEATH; PATHOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ASTROCYTES; CARRIER PROTEINS; CUPRIZONE; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; FATTY ACID-BINDING PROTEINS; HUMANS; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE TISSUE PROTEINS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84856617583     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. ARNETT HA, MASON J, MARINO M, SUZUKI K, MATSUSHIMA GK, TING JP. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 4: 1116-1122, 2001.
2. ARNETT HA, WANG Y, MATSUSHIMA GK, SUZUKI K, TING JP. Functional genomic analysis of remyelination reveals importance of inflammation in oligodendrocyte regeneration. J Neurosci 23: 9824-9832, 2003.
3. ASCHERIO A, MUNGER KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 61: 504-513, 2007.
4. BACK SA, TUOHY TM, CHEN H, WALLINGFORD N, CRAIG A, STRUVE J, LUO NL, BANINE F, LIU Y, CHANG A, TRAPP BD, BEBO BF Jr, RAO MS, SHERMAN LS. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat Med 11: 966-972, 2005.
5. BALENDIRAN GK, SCHNUTGEN F, SCAPIN G, BORCHERS T, XHONG N, LIM K, GODBOUT R, SPENER F, SACCHETTINI JC. Crystal structure and thermodynamic analysis of human brain fatty acid-binding protein. J Biol Chem 275: 27045-27054, 2000.
6. BANNERMAN P, HAHN A, SOULIKA A, GALLO V, PLEASURE D. Astrogliosis in EAE spinal cord: derivation from radial glia, and relationships to oligodendroglia. Glia 55: 57-64, 2007.
7. BARACSKAY KL, DUCHALA CS, MILLER RH, MACKLIN WB, TRAPP BD. Oligodendrogenesis is differentially regulated in gray and white matter of jimpy mice. J Neurosci Res 70: 645-654, 2002.
8. BARRY D, MCDERMOTT K. Differentiation of radial glia from radial precursor cells and transformation into astrocytes in the developing rat spinal cord. Glia 50: 187-197, 2005.
9. BIANCOTTI JC, KUMAR S, DE VELLIS J. Activation of inflammatory response by a combination of growth factors in cuprizone-induced demyelinated brain leads to myelin repair. Neurochem Res 33: 2615-2628, 2008.
10. BIBEL M, RICHTER J, SCHRENK K, TUCKER KL, STAIGER V, KORTE M, GOETZ M, BARDE YA. Differentiation of mouse embryonic stem cells into a defined neuronal lineage. Nat Neurosci 7: 1003-1009, 2004.
11. BRAUN A, DANG J, JOHANN S, BEYER C, KIPP M. Selective regulation of growth factor expression in cultured cortical astrocytes by neuro-pathological toxins. Neurochem Int 55: 610-618, 2009.
12. BRENNER M, JOHNSON AB, BOESPFLUG-TANGUY O, RODRIGUEZ D, GOLDMAN JE, MESSING A. Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet 27: 117-120, 2001.
13. CHANG A, NISHIYAMA A, PETERSON J, PRINEAS J, TRAPP BD. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci 20: 6404-6412, 2000.
14. CHANG A, TOURTELLOTTE WW, RUDICK R, TRAPP BD. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 346: 165-173, 2002.
15. CHANG ML, WU CH, JIANG-SHIEH YF, SHIEH JY, WEN CY. Reactive changes of retinal astrocytes and Muller glial cells in kainate-induced neuroexcitotoxicity. J Anat 210: 54-65, 2007.
16. CHARLES P, REYNOLDS R, SEILHEAN D, ROUGON G, AIGROT MS, NIEZGODA A, ZALC B, LUBETZKI C. Re-expression of PSA-NCAM by demyelinated axons: an inhibitor of remyelination in multiple sclerosis? Brain 125: 1972-1979, 2002.
17. CLARNER T, BUSCHMANN JP, BEYER C, KIPP M. Glial amyloid precursor protein expression is restricted to astrocytes in an experimental toxic model of multiple sclerosis. J Mol Neurosci 43: 268-274, 2011.
18. FAULKNER JR, HERRMANN JE, WOO MJ, TANSEY KE, DOAN NB, SOFRONIEW MV. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci 24: 2143-2155, 2004.
19. FENG L, HATTEN ME, HEINTZ N. Brain lipid-binding protein BLBP: a novel signaling system in the developing mammalian CNS. Neuron 12: 895-908, 1994.
20. FRANKLIN RJ, FFRENCH-CONSTANT C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 9: 839-855, 2008.
21. FURER M, HARTLOPER V, WILKINS J, NATH A. Lymphocyte emperipolesis in human glial cells. Cell Adhes Commun 1: 223-237, 1993.
22. GEURTS JJ, BARKHOF F. Grey matter pathology in multiple sclerosis. Lancet Neurol 7: 841-851, 2008.
23. GEURTS JJ, STYS PK, MINAGAR A, AMOR S, ZIVADINOV R. Gray matter pathology in chronic MS: modern views on an early observation. J Neurol Sci 282: 12-20, 2009.
24. GHATAK NR. Occurrence of oligodendrocytes within astrocytes in demyelinating lesions. J Neuropathol Exp Neurol 51: 40-46, 1992.
25. GODBOUT R, BISGROVE DA, SHKOLNY D, DAY RS. 3rd: Correlation of B-FABP and GFAP expression in malignant glioma. Oncogene 16: 1955-1962, 1998.
26. GOLD R, LININGTON C, LASSMANN H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129: 1953-1971, 2006.
27. GROEBE A, CLARNER T, BAUMGARTNER W, DANG J, BEYER C, KIPP M. Cuprizone treatment induces distinct demyelination, astrocytosis, and microglia cell invasion or proliferation in the mouse cerebellum. Cerebellum 8: 163-174, 2009.
28. HALLIDAY AM. Visual evoked potentials in demyelinating disease. Adv Neurol 31: 201-215, 1981.
29. HARSAN LA, STEIBEL J, ZAREMBA A, AGIN A, SAPIN R, POULET P, GUIGNARD B, PARIZEL N, GRUCKER D, BOEHM N, MILLER RH, GHANDOUR MS. Recovery from chronic demyelination by thyroid hormone therapy: myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging. J Neurosci 28: 14189-14201, 2008.
30. HASHIMOTO M, HOSSAIN S, YAMASAKI H, YAZAWA K, MASUMURA S. Effects of eicosapentaenoic acid and docosahexaenoic acid on plasma membrane fluidity of aortic endothelial cells. Lipids 34: 1297-1304, 1999.
31. IRVINE KA, BLAKEMORE WF. Remyelination protects axons from demyelination-associated axon degeneration. Brain 131: 1464-1477, 2008.
32. JARIUS S, PAUL F, FRANCIOTTA D, WATERS P, ZIPP F, HOHLFELD R, VINCENT A, WILDEMANN B. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 4: 202-214, 2008.
33. JARIUS S, WILDEMANN B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 6: 383-392, 2010.
34. JOHANN S, KAMPMANN E, DENECKE B, ARNOLD S, KIPP M, MEY J, BEYER C. Expression of enzymes involved in the prostanoid metabolism by cortical astrocytes after LPS-induced inflammation. J Mol Neurosci 34: 177-185, 2008.
35. JOHN GR, SHANKAR SL, SHAFIT-ZAGARDO B, MASSIMI A, LEE SC, RAINE CS, BROSNAN CF. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat Med 8: 1115-1121, 2002.
36. KARAKAYA S, KIPP M, BEYER C. Oestrogen regulates the expression and function of dopamine transporters in astrocytes of the nigrostriatal system. J Neuroendocrinol 19: 682-690, 2007.
37. KIPP M, CLARNER T, DANG J, COPRAY S, BEYER C. The cuprizone animal model: new insights into an old story. Acta Neuropathol 118: 723-736, 2009.
38. KIPP M, NORKUTE A, JOHANN S, LORENZ L, BRAUN A, HIEBLE A, GINGELE S, POTT F, RICHTER J, BEYER C. Brain-region-specific astroglial responses in vitro after LPS exposure. J Mol Neurosci 35: 235-243, 2008.
39. KOOIJMAN R, SARRE S, MICHOTTE Y, DE KEYSER J. Insulin-like growth factor I: a potential neuroprotective compound for the treatment of acute ischemic stroke? Stroke 40: e83-e88, 2009.
40. LASSMANN H. Multiple sclerosis pathology: evolution of pathogenetic concepts. Brain Pathol 15: 217-222, 2005.
41. LASSMANN H. Models of multiple sclerosis: new insights into pathophysiology and repair. Curr Opin Neurol 21: 242-247, 2008.
42. LENNON VA, WINGERCHUK DM, KRYZER TJ, PITTOCK SJ, LUCCHINETTI CF, FUJIHARA K, NAKASHIMA I, WEINSHENKER BG. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106-2112, 2004.
43. LI R, MESSING A, GOLDMAN JE, BRENNER M. GFAP mutations in Alexander disease. Int J Dev Neurosci 20: 259-268, 2002.
44. LIANG Y, DIEHN M, WATSON N, BOLLEN AW, ALDAPE KD, NICHOLAS MK, LAMBORN KR, BERGER MS, BOTSTEIN D, BROWN PO, ISRAEL MA. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 102: 5814-5819, 2005.
45. LIN W, KEMPER A, DUPREE JL, HARDING HP, RON D, POPKO B. Interferon-gamma inhibits central nervous system remyelination through a process modulated by endoplasmic reticulum stress. Brain 129: 1306-1318, 2006.
46. LINDNER M, FOKUHL J, LINSMEIER F, TREBST C, STANGEL M. Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination. Neurosci Lett 453: 120-125, 2009.
47. MA CS, NICHOLS KE, TANGYE SG. Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules. Annu Rev Immunol 25: 337-379, 2007.
48. MA D, ZHANG M, MORI Y, YAO C, LARSEN CP, YAMASHIMA T, ZHOU L. Cellular localization of epidermaltype and brain-type fatty acid-binding proteins in adult hippocampus and their response to cerebral ischemia. Hippocampus 20: 811-819, 2010.
49. MANA P, LINARES D, FORDHAM S, STAYKOVA M, WILLENBORG D. Deleterious role of IFNgamma in a toxic model of central nervous system demyelination: Am J Pathol 168: 1464-1473, 2006.
50. MASON JL, SUZUKI K, CHAPLIN DD, MATSUSHIMA GK. Interleukin-1beta promotes repair of the CNS. J Neurosci 21: 7046-7052, 2001.
51. MESSING A, HEAD MW, GALLES K, GALBREATH EJ, GOLDMAN JE, BRENNER M. Fatal encephalopathy with astrocyte inclusions in GFAP transgenic mice. Am J Pathol 152: 391-398, 1998.
52. MITA R, COLES JE, GLUBRECHT DD, SUNG R, SUN X, GODBOUT R. B-FABP-expressing radial glial cells: the malignant glioma cell of origin? Neoplasia 9: 734-744, 2007.
53. MOORE CS, ABDULLAH SL, BROWN A, ARULPRAGASAM A, CROCKER SJ. How factors secreted from astrocytes impact myelin repair. J Neurosci Res 89: 13-21, 2011.
54. NJENGA MK, MURRAY PD, MCGAVERN D, LIN X, DRESCHER KM, RODRIGUEZ M. Absence of spontaneous central nervous system remyelination in class II-deficient mice infected with Theiler's virus. J Neuropathol Exp Neurol 58: 78-91, 1999.
55. NORKUTE A, HIEBLE A, BRAUN A, JOHANN S, CLARNER T, BAUMGARTNER W, BEYER C, KIPP M. Cuprizone treatment induces demyelination and astrocytosis in the mouse hippocampus. J Neurosci Res 87: 1343-1355, 2009.
56. PATANI R, BALARATNAM M, VORA A, REYNOLDS R. Remyelination can be extensive in multiple sclerosis despite a long disease course. Neuropathol Appl Neurobiol 33: 277-287, 2007.
57. PATRIKIOS P, STADELMANN C, KUTZELNIGG A, RAUSCHKA H, SCHMIDBAUER M, LAURSEN H, SORENSEN PS, BRUCK W, LUCCHINETTI C, LASSMANN H. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 129: 3165-3172, 2006.
58. PEKNY M, LEVEEN P, PEKNA M, ELIASSON C, BERTHOLD CH, WESTERMARK B, BETSHOLTZ C. Mice lacking glial fibrillary acidic protein display astrocytes devoid of intermediate filaments but develop and reproduce normally. Embo J 14: 1590-1598, 1995.
59. PEKNY M, NILSSON M. Astrocyte activation and reactive gliosis. Glia 50: 427-434. 2005.
60. POTT F, GINGELE S, CLARNER T, DANG J, BAUMGARTNER W, BEYER C, KIPP M. Cuprizone effect on myelination, astrogliosis and microglia attraction in the mouse basal ganglia. Brain Res 1305: 137-149, 2009.
61. PRINEAS JW, BARNARD RO, KWON EE, SHARER LR, CHO ES. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 33: 137-151, 1993a
62. PRINEAS JW, BARNARD RO, REVESZ T, KWON EE, SHARER L, CHO E. Multiple sclerosis. Pathology of recurrent lesions. Brain 116 (Pt 3): 681-693, 1993b
63. QUINLAN RA, BRENNER M, GOLDMAN JE, MESSING A. GFAP and its role in Alexander disease. Exp Cell Res 313: 2077-2087, 2007.
64. RAKIC P. Neuron-glia relationship during granule cell migration in developing cerebellar cortex. A Golgi and electronmicroscopic study in Macacus Rhesus. J Comp Neurol 141: 283-312, 1971.
65. RAKIC P. Mode of cell migration to the superficial layers of fetal monkey neocortex. J Comp Neurol 145: 61-83, 1972.
66. RASH JE, YASUMURA T, DUDEK FE, NAGY JI. Cell-specific expression of connexins and evidence of restricted gap junctional coupling between glial cells and between neurons. J Neurosci 21: 1983-2000, 2001.
67. ROJAS CV, MARTINEZ JI, FLORES I, HOFFMAN DR, UAUY R. Gene expression analysis in human fetal retinal explants treated with docosahexaenoic acid. Invest Ophthalmol Vis Sci 44: 3170-3177, 2003.
68. SAIKALI P, CAYROL R, VINCENT T. Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica. Autoimmun Rev 9: 132-135, 2009.
69. SANAI N, ALVAREZ-BUYLLA A, BERGER MS. Neural stem cells and the origin of gliomas. N Engl J Med 353: 811-822, 2005.
70. SAWAISHI Y. Review of Alexander disease: beyond the classical concept of leukodystrophy. Brain Dev 31: 493-498, 2009.
71. SCHMID RS, YOKOTA Y, ANTON ES. Generation and characterization of brain lipid-binding protein promoterbased transgenic mouse models for the study of radial glia. Glia 53: 345-351, 2006.
72. SCOLDING N, FRANKLIN R, STEVENS S, HELDIN CH, COMPSTON A, NEWCOMBE J. Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis. Brain 121 (Pt 12): 2221-2228, 1998.
73. SIBBE M, FORSTER E, BASAK O, TAYLOR V, FROTSCHER M. Reelin and Notch1 cooperate in the development of the dentate gyrus. J Neurosci 29: 8578-8585, 2009.
74. SMITH KJ, BLAKEMORE WF, MCDONALD WI. Central remyelination restores secure conduction. Nature 280: 395-396, 1979.
75. STILLWELL W, WASSALL SR. Docosahexaenoic acid: membrane properties of a unique fatty acid. Chem Phys Lipids 126: 1-27, 2003.
76. TORKILDSEN O, BRUNBORG LA, MILDE AM, MORK SJ, MYHR KM, BO L. A salmon based diet protects mice from behavioural changes in the cuprizone model for demyelination. Clin Nutr 28: 83-87, 2009a.
77. TORKILDSEN O, BRUNBORG LA, THORSEN F, MORK SJ, STANGEL M, MYHR KM, BO L. Effects of dietary intervention on MRI activity, de- and remyelination in the cuprizone model for demyelination. Exp Neurol 215: 160-166, 2009b.
78. VAN DER VALK P, DE GROOT CJ. Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol Appl Neurobiol 26: 2-10, 2000.
79. VANA AC, FLINT NC, HARWOOD NE, LE TQ, FRUTTIGER M, ARMSTRONG RC. Platelet-derived growth factor promotes repair of chronically demyelinated white matter. J Neuropathol Exp Neurol 66: 975-988, 2007.
80. VEERKAMP JH, ZIMMERMAN AW. Fatty acid-binding proteins of nervous tissue. J Mol Neurosci 16: 133-142, discussion 151-157, 2001.
81. VENANCE L, CORDIER J, MONGE M, ZALC B, GLOWINSKI J, GIAUME C. Homotypic and heterotypic coupling mediated by gap junctions during glial cell differentiation in vitro. Eur J Neurosci 7: 451-461, 1995.
82. WHITE RE, MCTIGUE DM, JAKEMAN LB. Regional heterogeneity in astrocyte responses following contusive spinal cord injury in mice. J Comp Neurol 518: 1370-1390, 2010.
83. WOLSWIJK G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci 18: 601-609, 1998.